B - DEA IV Classification
C - $65M milestone payment from Eisai - 30 days
D - $5M milestone payment from Korean partner
E - EU approval soon, i.e., 26+ countries (with no competition)
F - Eisai has applied for early marketing and sales approval to begin in Jan. 2013
G - European partnership, like Eisai, in the wings (with additional milestone payments)
H - Launch of a $12B (annual) product begins worldwide first quarter of 2013.
I - Company has no debt
J - Company will have cash to develop pipeline of new products
K - Company has the capability to save the national healthcare system billions of dollars with Belviq
in its ability to 'help' solve the obesity issue and additionally treat those with diabetes
L - China partnership with ten of millions of potential obese/diabetic patients.
M - Diabetic indication for Belviq in sNDA.
N - PAH in pipeline